Dr. Moreau on the CASSIOPEIA Trial in Transplant-Eligible Myeloma

Phillippe Moreau, MD
Published: Friday, Aug 30, 2019



Phillippe Moreau, MD, head, Hematology Department, university professor of clinical hematology, University Hospital of Nantes, France, discusses the phase III CASSIOPEIA trial in transplant-eligible multiple myeloma.

For young fit patients, induction therapy with bortezomib (Velcade), thalidomide, and dexamethasone (VTd) followed by autologous stem cell transplantation (ASCT) and VTd consolidation is standard of care. In the pivotal CASSIOPEIA trial, investigators sought to enhance the current standard of care by evaluating the addition of daratumumab (Darzalex) to induction and consolidation therapy with the triplet.

In the first part of the trial, 1085 patients were randomized to receive induction and consolidation with daratumumab/VTd or VTd alone. Findings demonstrated that the rate of stringent complete response among patients treated with the quadruplet was 28.9% versus 20.3% in those treated with VTd alone. Patients who received the quadruplet also experienced an improvement in progression-free survival (HR, 0.47). Based on these data, the FDA granted a priority review to the supplemental biologics license application for the quadruplet therapy in transplant-eligible patients. The agency is expected to make its decision by September 26, 2019.
SELECTED
LANGUAGE


Phillippe Moreau, MD, head, Hematology Department, university professor of clinical hematology, University Hospital of Nantes, France, discusses the phase III CASSIOPEIA trial in transplant-eligible multiple myeloma.

For young fit patients, induction therapy with bortezomib (Velcade), thalidomide, and dexamethasone (VTd) followed by autologous stem cell transplantation (ASCT) and VTd consolidation is standard of care. In the pivotal CASSIOPEIA trial, investigators sought to enhance the current standard of care by evaluating the addition of daratumumab (Darzalex) to induction and consolidation therapy with the triplet.

In the first part of the trial, 1085 patients were randomized to receive induction and consolidation with daratumumab/VTd or VTd alone. Findings demonstrated that the rate of stringent complete response among patients treated with the quadruplet was 28.9% versus 20.3% in those treated with VTd alone. Patients who received the quadruplet also experienced an improvement in progression-free survival (HR, 0.47). Based on these data, the FDA granted a priority review to the supplemental biologics license application for the quadruplet therapy in transplant-eligible patients. The agency is expected to make its decision by September 26, 2019.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x